What is the primary difference between FDA Section 361 and Section 351 tissue products?

Section 361 products are minimally manipulated, intended strictly for homologous use, and regulated under 21 CFR Part 1271 without pre-market BLA approval. Section 351 products involve more-than-minimal manipulation or non-homologous use, requiring FDA pre-market approval through an Investigational New Drug (IND) application or Biologics License Application (BLA).

Does FDA registration mean an allograft is 'FDA Approved'?

No. FDA Establishment Registration (Form FDA 3356) means the facility has registered its location and listed its tissue products with the agency. It does not constitute formal FDA testing, approval, or endorsement of the product's safety or clinical efficacy.

How long must a medical practice retain tissue procurement and patient tracking records?

Federal GTP standards under 21 CFR 1271 and general state medical board guidelines typically require tissue tracking records to be retained for a minimum of 10 years, though practices should verify specific local and state storage mandates.

What happens if a practice uses an allograft that non-compliantly acts as an unapproved Section 351 drug?

Using non-compliant products can expose a practice to regulatory warning letters, state medical board sanctions, loss of malpractice coverage for unapproved drug administration, and mandatory product forfeitures or recalls.

FDA Section 361 Compliance Checklist for Allografts

FDA Section 361 compliance for biologic allograft procurement requires medical practices to verify that human cells, tissues, and cellular and tissue-based products (HCT/Ps) strictly adhere to 21 CFR Part 1271 guidelines, including minimal manipulation and homologous use standards. Practice managers and clinical directors must maintain rigorous vendor auditing protocols covering FDA registration, donor eligibility screening, current Good Tissue Practice (cGTP), and complete chain-of-custody tracking. Establishing an end-to-end compliance process safeguards clinical licensure, ensures regulatory integrity, and protects patient safety during tissue procurement.

Understanding 21 CFR Part 1271: Section 361 vs. Section 351 Criteria

The regulatory pathway for human cellular and tissue-based products is defined by Title 21 of the Code of Federal Regulations (21 CFR Part 1271). Within this framework, the Food and Drug Administration (FDA) categorizes tissue products under two distinct regulatory pathways: Section 361 and Section 351 of the Public Health Service (PHS) Act.

Section 361 HCT/Ps are regulated solely under 21 CFR Part 1271 and do not require pre-market approval, clinical trials, or a Biologics License Application (BLA), provided they meet four strict criteria:

Minimal Manipulation: Processing must not alter the original relevant biological characteristics of the tissue.
Homologous Use: The tissue must perform the same basic function in the recipient as it performed in the donor (e.g., providing structural support, cushioning, or covering barriers).
No Combination: The product must not be combined with another drug or device, except for authorized water, crystalloids, or sterilizing agents.
Metabolic Independence / Autologous relative use: The tissue must not depend on metabolic activity for its primary function, or if it does, it must be intended for autologous use, allogeneic use in a first- or second-degree blood relative, or reproductive use.

If a product fails to meet any one of these criteria, it is classified as a Section 351 biologic, drug, or medical device. Section 351 products require an Investigational New Drug (IND) application or an approved BLA prior to clinical distribution. Sourcing products promoted as Section 361 allografts that actually operate under Section 351 rules introduces significant regulatory and operational liability for a medical facility.

FDA Section 361 Compliance Checklist for Biologic Allograft Procurement

When evaluating biologics suppliers, practice administrators should complete a systematic audit before purchasing or deploying human tissue products. The following structured checklist provides the baseline verification standards required for clinical compliance.

1. Vendor & Manufacturer Registration Verification

[ ] FDA Form 3356: Confirm the tissue manufacturer and primary processor hold an active FDA Establishment Registration and Tissue Listing (Form FDA 3356).
[ ] State Licensure: Verify that the supplier holds appropriate tissue bank permits for state-level distribution, such as Texas tissue bank registration or equivalent state licensing.
[ ] AATB Accreditation: Determine whether the tissue processor is accredited by the American Association of Tissue Banks (AATB), ensuring voluntary adherence to rigorous quality standards.

2. Regulatory Classification & Processing Verification

[ ] Minimal Manipulation Attestation: Review manufacturer processing documentation to confirm tissue structure is preserved without enzymatic digestion, chemical modification, or cell expansion.
[ ] Homologous Use Labeling: Inspect product package inserts and marketing collateral to verify that all clinical indications and promotional materials strictly cite homologous applications (e.g., connective tissue supplementation or wound covering).
[ ] No Unapproved Additives: Ensure the tissue is packaged without systemic active ingredients, unapproved peptides, or synthetic scaffolding compounds.

3. Donor Screening & Testing Integrity

[ ] Communicable Disease Screening: Confirm compliance with 21 CFR 1271 Subpart C, requiring donor screening for relevant communicable diseases (including HIV, Hepatitis B, Hepatitis C, Syphilis, and HTLV).
[ ] Summary of Records (SOR): Ensure each tissue lot includes a formal Certificate of Analysis (CoA) and a Donor Eligibility Summary signed by a licensed Medical Director.
[ ] CLIA-Certified Testing: Verify that all serological and nucleic acid testing (NAT) was performed by a CLIA-certified laboratory using FDA-cleared donor screening tests.

4. Storage, Handling, and Chain of Custody

[ ] cGTP Compliance: Confirm the manufacturer operates under current Good Tissue Practice (cGTP) regulations pursuant to 21 CFR 1271 Subpart D.
[ ] Cold Chain Documentation: Verify shipping protocols and temperature logging standards (e.g., ambient, refrigerated, cryogenic dry ice) from the central storage depot to the clinic receiving dock.
[ ] Lot Tracking Protocol: Ensure the vendor provides tissue tracking logs that allow the clinic to trace a unique tissue identification number (TIN) directly to the receiving patient chart.

Clinical vs. Operational Perspectives on Biologic Procurement

Successful tissue procurement requires alignment between the clinical objectives of attending physicians and the risk management duties of practice administrators.

Clinical Considerations

For regenerative medicine doctors and clinical specialists, product integrity, cellular viability parameters, handling characteristics, and clinical handling protocols are paramount. Clinicians rely on predictability in tissue structural function—such as extracellular matrix integrity in amnion or connective tissue matrix allografts—to support surgical or procedural outcomes. Clinicians must ensure that their documented procedure notes strictly match homologous use criteria, documenting structural supplementation or wound care indications rather than systemic or disease-modifying outcomes.

Operational and Administrative Considerations

For practice managers, administrators, and procurement personnel, the primary focus centers on supply chain reliability, legal compliance, risk mitigation, and clear cost management. Operational leads must manage:

Inventory Holding Costs: Balancing shelf-life constraints (ambient vs. cryopreserved storage at -80°C) against patient volume.
Liability Mitigation: Ensuring the clinic does not store or administer unapproved Section 351 biological drugs, which can jeopardize malpractice coverage and medical board compliance.
Documentation Archival: Maintaining tissue tracking logs for a minimum of 10 years (or as required by state law) to fulfill audit requirements in the event of a regulatory inquiry or manufacturer recall.

Identifying Regulatory Red Flags in Vendor Documentation

Practices evaluating new vendor options should monitor for common compliance warning signs during the vendor onboarding process:

Disease Treatment Claims: Promotional materials claiming the allograft cures, treats, or mitigates systemic conditions (e.g., autoimmune disorders, neurodegenerative conditions, or organ failure) indicate a Section 351 drug classification.
Unregistered Facilities: Inability of the distributor to supply the direct manufacturer's FDA Establishment Identifier (FEI) or Form 3356.
Missing Lot Specifics: Receiving bulk allograft vials without individual donor eligibility records or unique tissue identification numbers.
Vague Processing Descriptions: Vendor reluctance to provide transparent information regarding tissue processing methods, cryoprotectants used, or terminal sterilization protocols.

What This Means for Your Practice

Adopting a formal compliance protocol for tissue procurement protects clinic operations while ensuring patient safety. To align your practice with current FDA standards, execute the following actions:

Conduct an Inventory Audit: Cross-reference all current allograft tissue inventory against FDA registration listings and verify that complete donor records exist for every lot on site.
Standardize Receiving Workflows: Train medical assistants and practice managers to inspect shipment temperature indicators, log unique tissue identification numbers, and archive Certificates of Analysis upon delivery.
Review Clinical Documentation Templates: Audit procedure note templates in your Electronic Health Record (EHR) system to ensure documentation reflects homologous application and structural indication.
Establish Approved Vendor Criteria: Require all procurement partners to complete an annual regulatory compliance questionnaire and submit updated FDA registration documents.

Sourcing Compliant Allografts

Navigating tissue procurement requires a strict commitment to quality assurance, regulatory compliance, and operational transparency. Establishing robust auditing workflows ensures your practice operates within clear federal parameters while maintaining continuous supply chain safety. To review your practice's procurement protocols, explore our educational resources on biologics and review regulatory standards in our practice faq section. For specialized guidance on vendor evaluation or compliance documentation, contact our team to schedule a practice contact consultation.